Aurobindo Pharma, a drug maker based in Hyderabad, earned a consolidated net profit of ₹1,124 crore in the July to September quarter. That is up from ₹848 crore a year ago, according to The Hindu BusinessLine. Revenue rose 24% to a record ₹10,263 crore.
The company also plans to pay a dividend. Shareholders will get it by 20 November, according to NDTV Profit. For people who own the shares, both sales and profit grew strongly this quarter.
What happened
The results are for the second quarter of the financial year 2026-27, called Q2 FY27. The quarter ended on 30 September 2026. Aurobindo shared the numbers in a release on Wednesday, 4 November 2026.
The Hindu BusinessLine says this was the company's highest revenue ever for a single quarter. The company said growth came from all of its businesses. The reports do not say which product or country grew the most.
The reports also do not give the dividend amount per share or the record date. Readers who want these details should check the company's filing on the BSE or NSE website.
The numbers
| Item | Q2 FY27 | Same quarter last year | Change |
|---|---|---|---|
| Revenue | ₹10,263 crore | ₹8,286 crore | Up 24%, or ₹1,977 crore (our calculation) |
| Consolidated net profit | ₹1,124 crore | ₹848 crore | Up 32.5% (BusinessLine) or 33% (NDTV Profit); ₹276 crore more (our calculation) |
| Net profit margin | About 11.0% (our calculation) | About 10.2% (our calculation) | Up about 0.8 percentage points (our calculation) |
The table compares this quarter with the same quarter a year ago. The last row shows how much profit the company kept from its revenue.
Here is a simple way to read it. In Q2 FY27, Aurobindo kept about ₹11 as profit from every ₹100 of revenue, by our calculation. A year earlier, it kept about ₹10.20. So profit grew faster than sales. This usually means costs rose more slowly than income. The reports do not give a cost breakdown, so we cannot say which costs changed.
Where the reports differ
Both reports agree on the profit amounts, but not on the growth rate. The Hindu BusinessLine says net profit rose 32.5%. The headline of the NDTV Profit report says profit rose 33%. We could not confirm which figure the company used in its own filing.
Our own calculation, using ₹1,124 crore and ₹848 crore, gives a rise of about 32.5%. Readers can check the exact figure in the results filing on the BSE or NSE website.
On revenue, the two reports match. Both give ₹10,263 crore for this quarter against ₹8,286 crore a year ago, a rise of 24%.
What the company said
K. Nithyananda Reddy is the Vice-Chairman and Managing Director of Aurobindo Pharma. He said the quarter showed "the strength of our business fundamentals, sustained execution and the resilience of our diversified product portfolio". In plain words, the basic business is sound, the company carried out its plans well, and selling many different medicines helped it stay steady.
He said growth came from "healthy organic momentum across our key businesses and the successful integration of inorganic opportunities". So part of the growth came from the company's own existing work. Another part came from businesses it brought in from outside. The reports do not name those businesses.
Looking ahead, he said the company will focus on "sustainable growth, financial discipline and creating long-term value". He also said it wants to make good, affordable medicines available to more people worldwide. These are the company's goals, not results. The reports give no targets or numbers for them.
Why it matters to a common investor
Quarterly results work like a report card. They show whether a company is selling more and keeping more of what it earns. On both counts, Aurobindo's Q2 was strong. It had record revenue, and its profit margin improved, by our calculation.
Companies in the same sector can have very different quarters. Rival drug maker Biocon saw its Q2 profit fall because some shipments slipped into October. Meanwhile, Emcure Pharma reported higher Q2 profit. So one company's results do not tell you about the whole sector.
A dividend is cash paid straight to shareholders, so its value does not depend on the share price. But a good quarter alone does not tell you whether a share is cheap or costly. The reports also do not say how the shares moved after the results. More results from this season are on our results page.
Risks to keep in mind
- One quarter is a short time. A strong quarter does not mean the next one will be as good. It helps to look at results over several quarters.
- Few details so far. The reports do not split revenue by business or country. So it is hard to know which part drove the growth.
- Growth from added businesses. The company says some growth came from businesses it brought in. Such growth can be harder to repeat. Joining new businesses can also bring extra costs.
- Dividend details are missing. The amount is not in the reports. Confirm it in the official filing before counting on it.
What to watch next
- The full results filing on BSE or NSE. It should show the dividend amount, the record date and business-wise numbers.
- The dividend payment, which NDTV Profit says will be made by 20 November.
- Any details on the businesses the company has added, and how much revenue they bring.
- Whether profit keeps growing faster than revenue in the coming quarters.
Words explained
- Consolidated net profit: The profit of a company and the companies it owns, added together, after all costs and taxes are paid.
- Revenue: The total money a company earns from sales before it pays any costs.
- Q2 FY27: The second quarter of the financial year 2026-27, which runs from July to September 2026. In India, the financial year runs from April to March.
- Net profit margin: Profit shown as a share of revenue. A 10% margin means ₹10 of profit for every ₹100 of sales.
- Percentage points: The simple gap between two percentages. A move from 10% to 11% is a rise of 1 percentage point.
- Dividend: A part of a company's profit paid to shareholders in cash, usually a fixed amount for each share.
- Record date: The date on which you must be on the company's list of shareholders to get a dividend.
- Organic and inorganic growth: Organic growth comes from a company's own existing businesses. Inorganic growth comes from buying or joining with other businesses.
Sources: The Hindu BusinessLine, NDTV Profit.
This article is for information and education only. It is not investment advice. MarketUpDown is not registered with SEBI as an investment adviser or research analyst. Read our disclaimer.